- Home
- DYN vs LIVN Comparison
DYN vs LIVN Comparison
Compare DYN & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- LIVN
- Stock Information
- Founded
- DYN 1984
- LIVN 1987
- Country
- DYN United States
- LIVN United Kingdom
- Employees
- DYN N/A
- LIVN N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DYN Health Care
- LIVN Health Care
- Exchange
- DYN Nasdaq
- LIVN Nasdaq
- Market Cap
- DYN 1.9B
- LIVN 2.1B
- IPO Year
- DYN 2020
- LIVN 1993
- Fundamental
- Price
- DYN $13.15
- LIVN $54.53
- Analyst Decision
- DYN Strong Buy
- LIVN Strong Buy
- Analyst Count
- DYN 14
- LIVN 7
- Target Price
- DYN $34.93
- LIVN $59.71
- AVG Volume (30 Days)
- DYN 2.2M
- LIVN 583.7K
- Earning Date
- DYN 11-11-2025
- LIVN 10-29-2025
- Dividend Yield
- DYN N/A
- LIVN N/A
- EPS Growth
- DYN N/A
- LIVN N/A
- EPS
- DYN N/A
- LIVN N/A
- Revenue
- DYN N/A
- LIVN $1,309,329,000.00
- Revenue This Year
- DYN N/A
- LIVN $11.29
- Revenue Next Year
- DYN N/A
- LIVN $6.59
- P/E Ratio
- DYN N/A
- LIVN N/A
- Revenue Growth
- DYN N/A
- LIVN 8.23
- 52 Week Low
- DYN $6.36
- LIVN $32.48
- 52 Week High
- DYN $37.08
- LIVN $58.91
- Technical
- Relative Strength Index (RSI)
- DYN 56.80
- LIVN 50.60
- Support Level
- DYN $12.65
- LIVN $56.42
- Resistance Level
- DYN $13.68
- LIVN $57.53
- Average True Range (ATR)
- DYN 0.67
- LIVN 1.35
- MACD
- DYN -0.16
- LIVN -0.70
- Stochastic Oscillator
- DYN 30.72
- LIVN 10.25
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.